Novalgen_logo_on_white.jpg
NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting
December 10, 2023 21:00 ET | NovalGen Ltd.
NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222
Novalgen_logo_on_white.jpg
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023 15:18 ET | NovalGen Ltd.
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
Novalgen_logo_on_white.jpg
NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting
November 03, 2022 09:58 ET | NovalGen Ltd.
-Updated clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL -- Pre-clinical data for a first in class half-life extended T Cell engager...
Novalgen_logo_on_white.jpg
NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting
May 26, 2022 18:00 ET | NovalGen Ltd.
- First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...